Drug Trial Radar · NCT06422884
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
213
Actual
Start
Nov 15, 2024
Primary completion
Aug 21, 2026
Study completion Aug 21, 2026
Sponsor
- Lead sponsor
- Endeavor Biomedicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.
Conditions
- Idiopathic Pulmonary Fibrosis
- Progressive Fibrosing Interstitial Lung Disease
Interventions
ENV-101Drug
oral tablet, dosed once a day
PlaceboDrug
oral tablet, dosed once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in percent predicted forced vital capacity (ppFVC) compared to placeboTime frame: Baseline and Week 24
Locations
78 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Mendoza, Argentina
Research Site
Mendoza, Argentina
Research Site
Quilmes, Buenos Aires, Argentina
Research Site
Camperdown, New South Wales, Australia
Research Site
Macquarie Park, New South Wales, Australia
Research Site
Brisbane, Queensland, Australia
Research Site
South Brisbane, Queensland, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Nedlands, Western Australia, Australia
Research Site
Vienna, Austria
Research Site
Graz, Styria, Austria
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Dinant, Namur, Belgium
Research Site
Edmonton, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Ajax, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Trois-Rivières, Quebec, Canada
Research Site
Angers, France
Research Site
Bordeaux, France
Research Site
Caen, France
Research Site
Dijon, France
Research Site
Montpellier, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Paris, France
Research Site
Rennes, France
Research Site
Tours, France
Research Site
Berlin, Germany
Research Site
Leipzig, Germany
Research Site
Giessen, Hesse, Germany
Research Site
Immenhausen, Hesse, Germany
Research Site
Hanover, Lower Saxony, Germany
Research Site
Essen, North Rhine-Westphalia, Germany
Research Site
Dublin, Ireland
Research Site
Dublin, Leinster, Ireland
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.